UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors [PDF]
, 2020 Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders.
Beleggia, Filippo +7 more
core +1 more source
Scientific Reports, 2023 Olaparib is a PARP inhibitor (PARPi) approved for targeted treatment of ovarian cancer (OC). However, its efficacy is impeded by the inevitable occurrence of resistance.
Łukasz Biegała +5 more
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]
, 2017 The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects.
De Felice, Francesca +4 more
core +2 more sources
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer
Translational Oncology, 2019 Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option.
Alan P Lombard +9 more
doaj +1 more source
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]
, 2017 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don +20 more
core +2 more sources
Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
Journal of Obstetrics and Gynaecology, 2023 This study aimed to evaluate the efficacy and safety of olaparib for the treatment of advanced ovarian cancer. All studies that assessed the efficacy and safety of olaparib in advanced ovarian cancer were searched in PubMed, Embase, and Web of Science ...
Yuanyuan Yang +4 more
doaj +1 more source
Niraparib in ovarian cancer. results to date and clinical potential [PDF]
, 2017 Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi +5 more
core +1 more source
Research, 2023 Platinum-based chemotherapy remains the main systemic treatment of ovarian cancer (OC). However, the inevitable development of platinum and poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) resistance is associated with poor outcomes ...
Yangyang Li +7 more
doaj +1 more source
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy [PDF]
, 2013 Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant forms of endogenous DNA breakage, contributing to hereditary ataxia and underlying the cytotoxicity of a wide range of anti-cancer agents.
Alagoz +50 more
core +1 more source